Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.3 EUR | -0.65% | +0.08% | +1.72% |
May. 03 | GSK plc : Back on track | |
May. 02 | European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.72% | 123B | B+ | ||
+26.08% | 681B | C+ | ||
+21.85% | 556B | B | ||
-4.77% | 361B | C+ | ||
+16.97% | 325B | B- | ||
+5.69% | 285B | C+ | ||
+13.68% | 235B | B+ | ||
+3.65% | 199B | B- | ||
-11.12% | 189B | A+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi